IGXT (MC $32 M) 2 FDA Approvals coming + 2 new NDA filings in 4Q =10+ Bagger Gem

Discussion in 'Stock picks and trading strategies' started by DollarChamp, Jul 19, 2016.

  1. DollarChamp

    DollarChamp Member

    Undiscovered Intelgenx (IGXT) is definitely one of the most attractive and undervalued stock in the Biotech Sector . The Company has already 2 Drugs approved and another 2 Big Drugs close to FDA approval .BIG Partnership News could come any day for up to 3 Drugs for which IGXT got a Therm Sheet from a Global Pharma Company and there is another partnering discussion ongoing for 2 Drugs (see pipeline chart below) .

    IGXT has a ridiculous Market Cap of less than $32 Million which is a Big Joke for a Company with such a MEGA Product Pipeline , this Co has everything to be the next 10 Bagger minimum .GL

    Intelgenx (IGXT)

    Market Cap: $31.8 Million
    Cash: $2.1 Million
    Price: $0.49

    Burn-Rate: $400k per Quarter
    Shares Out : 63.6 Million

    •Announced a development and commercialization term sheet with a global pharmaceutical company for up to three products. If entered into, IntelGenx expects the definitive agreement to be finalized in the second quarter of 2016

    Product :Rizaport (Migraine)
    •European Mktg Approval–November 2015
    •Planned USA submission to FDA Q4/2016
    •Expected USA launch Q2/2017

    Product :Tadalafil (Erectile Dysfunction) a better Oral thin-film version of Blockbuster Drug Cialis
    •505(b)(2) USA NDA submission in Q4/2016
    •Expected USA launch Q4/2017

    Product :Indicated for Opioid Dependence
    •Awaiting FDA approval
    •According to IMS data, the oral film market for opioid dependence was worth more than $1.4B US in 2014.

    Presentation July 2016



  2. DollarChamp

    DollarChamp Member

  3. DollarChamp

    DollarChamp Member

    Strong Insider & Institutional Ownership on this Goldmine . Big Jump to new highs could come anytime now .GL

    Insider Ownership :

    Horst G. Zerbe 4,670,243.5 7.34%
    Ingrid Zerbe 5,471,356.5 8.60%
    Bernard J. Boudreau 287,500
    Bernd Melcher 232,500
    Andre Godin 214,500
    Ian Troup 187,500
    John Marinucc 175,000
    Nadine Paiement 135,000
    Clemens Mayr 68,750
    John Durham 50,000
    Robert Bechard 10,000

    All directors and officers as a group (11 persons) 11,502,351 18.08%

    Institutional Holders :
    Alpha Capital ...3.2M
    Roadmap Capital Inc. 3.1M

    Insider activity

    BECHARD ROBERT J. Officer Purchase at $0.47 - $0.51 per share. Direct 4,900 Jan 22, 2016 10,000

    BOUDREAU BERNARD Director Purchase at $0.51 - $0.51 per share. Indirect 6,120 Jan 22, 2016 12,000

    BOUDREAU BERNARD Director Purchase at $0.51 - $0.51 per share. Direct 19,000 Jan 22, 2016 38,000

    BOUDREAU BERNARD Director Purchase at $0.45 - $0.45 per share. Indirect 3,375 Jan 21, 2016 7,500

    GODIN ANDRE Officer Purchase at $0.40 - $0.4 per share. Direct 8,000 Jan 20, 2016 20,000

    BOUDREAU BERNARD Director Purchase at $0.41 - $0.41 per share. Indirect 3,075 Jan 20, 2016 7,500

    GODIN ANDRE Officer Purchase at $0.52 - $0.52 per share. Direct 4,940 Dec 30, 2015 9,500

    GODIN ANDRE Officer Purchase at $0.51 - $0.51 per share. Direct 7,828 Dec 23, 2015 15,350

    GODIN ANDRE Officer Purchase at $0.50 - $0.51 per share. Direct 6,640 Dec 22, 2015 13,150

    GODIN ANDRE Officer Purchase at $0.50 - $0.5 per share. Direct 3,250 Dec 21, 2015 6,500
  4. DollarChamp

    DollarChamp Member

    Here is one of the reason why i like this stock so much is because of this thin-flim version of the Blockbuster Cialis which works faster than tablet . There are NO generics available on the Markets so IGXT could capture a significant market share with their better version . NDA submission expected in 4Q and FDA approval late 2017 .This Drug alone is worth more than $2 per share and they have a full Pipeline of Drugs which are close to Market entry .

    Product :Tadalafil (Erectile Dysfunction)
    •505(b)(2) USA NDA submission in Q4/2016
    •Expected USA launch Q4/2017

    Wafer Viagra For Instant Results One of the big challenges for erectile dysfunction medicine manufacturers is to quicken the time between the application of the medicine and its response. Men want instant results when they take Viagra, Cialis or Levitra and complain that having to wait as much as thirty minutes before the active ingredient is effective can burst the bubble of spontaneity and passion which are often essential requirements of good sex. Well a solution could be at hand following research done by a Canadian research company called IntelGenx who have developed wafers [like the common breath freshness ones] that are designed to melt on your tongue which they say will get the medicine into your bloodstream around 30% faster than by using conventional tablets. IntelGenx say that because the mouth is lined with tiny blood vessels applying the wafer Viagra here can give a very fast application of the drug directly into the bloodstream. IntelGenx said that they would be conducting more clinical trials to corroborate this and they hoped to develop a whole range of fast acting wafer medications to treat not only erectile dysfunction but also pain relief, depression and hypertension. Sometimes men complain that if they have eaten a large meal it can take an even longer time for the Viagra, Cialis and Levitra to take effect. If on the other hand they made use of erectile dysfunction medication in a wafer form applied directly to the mouth and therefore bypassing their digestive system this problem would disappear. Using a wafer type of Viagra would also mean that you wouldn't have to go and get a glass of water in the middle of a passionate encounter in order to swallow your pill. Wafer Viagra would be a much more discreet application of impotence medication and Ukmedix News will be looking out for updates on the IntelGenx clinical testing done on this new ideaReport TOU Violation
  5. DollarChamp

    DollarChamp Member

  6. DollarChamp

    DollarChamp Member

  7. DollarChamp

    DollarChamp Member

    And up she goes again i love this stock . Market cap of $46 million still laughable for this undiscovered Goldmine

  8. DollarChamp

    DollarChamp Member

    Great News released Friday after hour , now they have a lot of Cash for 3 years but they could be already profitable by next year .

    IntelGenx Announces Sale of Forfivo XL(R) Royalty for $6 Million....August 05, 2016

    The Drug Montelukast mentioned below in the article alone is worth multiple times the current market cap of laughable $46 Million .If everything goes well with the potential Blockbuster Drug then IGXT will be the next Billion Dollar Company .With the large Pipeline they have and the terrible brutally low Valuation this stock is a Lifetiime opportunity .GL

    [The wonder pill that could STOP your brain ageing: Common asthma drug may be a cure for Alzheimer's, claims study

    IntelGenx to Initiate Phase 1 Trial of Montelukast

    IntelGenx expects results from the phase 1 trial to be available in September 2016. Following the completion of the phase 1 results, the Company will begin preparation work to initiate a phase 2 study where patients will be enrolled. IntelGenx will be actively seeking a partnership or alliance opportunity to complete the remaining developmental work and commercialization of this product.

    "Montelukast is by far the most important and promising drug repurposing opportunity that the company has in its product pipeline," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "IntelGenx with Dr. Aigner, is taking a leadership position in this most serious unmet need affecting millions globally. The market for degenerative diseases of the brain is a multi-billion-dollar opportunity for the company. We look forward to communicating the results from the phase 1 study and advancing montelukast forward to reach its full potential."
  9. DollarChamp

    DollarChamp Member

    Shorts tried hard to kill momentum yesterday but they will lose the Game because the Stock is terrible Undervalued und there is to much News on the way so every dip below $1 is a great buying opportunity .

    IntelGenx Technologies Corp (OTCMKTS:IGXT) Is Today’s Pharma Focus.....Tuesday, 09 Aug 2016

    Currently trading with a market cap of $39 million, IGXT is one OTC pharma stock that has a lot in the pipeline. All it needs is one product to hit, and the company will be worth 10x its current market cap. IGXT has multi-bagger written all over it. We’ll know more after the markets close on August 11th when the company reports second quarter results and provides an update on the earnings call.
  10. DollarChamp

    DollarChamp Member

    A lot of new Partnerdeals on the way which means Upfront Payments to the Company . Market Cap of $43 Million is still laughable for this Goldmine .GL

    Transcript Q2 released last Thursday

    With respect to other BD activities, we're clearly focusing right now in the business development area on bringing in new deals. For example at the recent BIO Conference, we met with 50 different pharmaceutical companies to discuss partnering opportunities, and we're currently in discussions with eight companies that are interested in RIZAPORT licenses, 17 companies that are interested in our Tadalafil product, three companies are interested in our schizophrenia drug, and five companies have expressed interest in a deal on Forfivo outside of the US.

    Above and beyond that, there are ongoing late-stage discussions with a global pharmaceutical company for multiple products with the potential goal of finalizing a definitive agreement in the third quarter of 2016
  11. DollarChamp

    DollarChamp Member

  12. DollarChamp

    DollarChamp Member

  13. DollarChamp

    DollarChamp Member

    GREAT NEWS OUT .. and stock is stiill terrible underpriced at a market cap of laughable $52 Million .GL


    IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain
    August 22, 2016

    "We are very pleased by the results of the study which confirmed that our Montelukast VersaFilm™ significantly improves the bioavailability of the drug when given as an oral film product. The study demonstrates that the VersaFilm™ technology is an effective delivery system for CNS applications," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "Montelukast is an important drug repurposing opportunity that the company has in its product pipeline which could potentially become a multi-billion-dollar product in the large and underserved market for degenerative diseases of the brain."
  14. DollarChamp

    DollarChamp Member

  15. DollarChamp

    DollarChamp Member

  16. DollarChamp

    DollarChamp Member

  17. DollarChamp

    DollarChamp Member

  18. DollarChamp

    DollarChamp Member

    Very close to break through the $1 Mark then real rally will begin . stock is still terrible undervalued with a market cap of of $60 m
  19. DollarChamp

    DollarChamp Member

  20. DollarChamp

    DollarChamp Member

    Heavily undervalued stock with so many big milestones on the way , could be hottest and cheapest FDA play for the next 9-12 months . This Stock could run to $3+ before FDA decision .GL

    Market cap $55 million

    Upcoming Milestones:

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July

    NDA resubmission for Rizaport (migraine) in early Q3

    Start Phase 2a of Montelukast (Alzheimer Disease ) potential Blockbuster

    Partnership for Tadalafil could come anytime now

    Partnership for Rizaport for EU and USA could also happen anytime now

    IntelGenx has multi-faceted BD approach for its oral films May 16, 2017..

    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Monster Pipeline

Share This Page